Budget Impact of Venetoclax for Newly Diagnosed Patients with Acute Myeloid Leukemia Aged ≥ 75 Years or with Comorbidities Precluding Intensive Chemotherapy in the United States
Inclusion of venetoclax combinations for newly diagnosed patients with AML aged ≥ 75 years or with comorbidities precluding intensive chemotherapy reduced the budget impact, providing potential financial benefits for US payers.
Authors
- Melissa Montez
- Thomas W. LeBlanc (ORCID: https://orcid.org/0000-0002-0546-7895)
- Yiqing Xu
- Xinglei Chai
- Kaylee Miu
- Janet Nguyen (ORCID: https://orcid.org/0009-0006-1295-2238)
- Xin Chen
- Chia-Wei Lin
Institutions
- AbbVie (United States) (US)
- Duke Medical Center (US)
- Analysis Group (United States) (US)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2026-03-12
- DOI
- https://doi.org/10.1007/s12325-026-03542-2
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Comprehensive Cancer Network